

Research Article Surgical Management for Refractory Bleb Dysesthesia

Agnieszka Dyrda (),¹ Alfonso Anton,^{1,2} Juan Pablo Figueroa-Vercellino (),³ and Marta Pazos³

¹Institut Català de la Retina (ICR), Barcelona, Spain

²Universitat Internacional de Catalunya (UIC), Barcelona, Spain ³Institut Clínic d'Oftalmologia, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain

Correspondence should be addressed to Agnieszka Dyrda; agnieszkaannadyrda@wp.pl

Received 6 March 2020; Accepted 25 June 2020; Published 4 August 2020

Guest Editor: Giacinto Triolo

Copyright © 2020 Agnieszka Dyrda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To present long-term results of modified bleb-limiting conjunctivoplasty as a successful treatment for intractable bleb dysesthesia and to review the literature on the surgical management of dysesthetic bleb. Methods. Consecutive case series and literature review. We present four cases of surgically reduced painful blebs. Our technique consisted of the following steps: (1) conjunctival, radial incision to the bare sclera in the desired limit of the bleb; (2) suturing with buried, interrupted sutures at the nearest edge of the filtering bleb; (3) lower limbal peritomy including unwanted area of the extended bleb; (4) dissection and removal of the underlying fibrous tissue when present; (5) conjunctival and resorbable sutures. In addition, a systematic literature review was performed. Only reports presenting outcomes of surgical treatment of bleb dysesthesia after filtering procedure were included in review. Results. Four eyes were included consecutively in the study in a period of 4 years. On average, they developed circumferential bleb dysesthesia 9.3 ± 4.7 months after uneventful combined phacotrabeculectomy with Mitomycin C as primary procedure. Surgical reduction was decided after failure of lubricants in controlling ocular discomfort. Two cases showed a dense fibrous tissue beneath the conjunctiva that was excised to ensure filtration. In all cases, a rapid disappearance of symptoms with very good aesthetic and functional outcome was observed. After 12-month follow-up, patients remained asymptomatic and maintained intraocular pressure of 10.7 ± 1.2 mmHg without treatment. A systematic review of the literature obtained 15 eligible case series (n = 123) with rates of success within 46-100%, favoring less aggressive approaches to reduce bleb size. Conclusion. Bleb dysesthesia is a rare complication of filtering glaucoma surgery. This modified bleb-limiting conjunctivoplasty technique (with removal of subjacent fibrous tissue if present) is able to target the underlying etiology providing ocular discomfort relief while maintaining bleb function and may be considered as first-choice surgical treatment.

1. Introduction

In 1977, Cohen et al. proposed classifying dysfunctional filtering blebs into three basic categories: underfiltration, overfiltration, and excessive size [1]. Bleb dysesthesia is an uncommon complication of glaucoma filtration surgery in which a well-functioning, but large filtering bleb with adequate intraocular pressure (IOP) control causes ocular discomfort [2–4] due to the effect of interrupted tear film distribution over the bleb and cornea [5].

There are many described methods for managing dysesthesia. Intensive surface lubrication is universally used. Other nonsurgical methods that stimulate scarring (i.e., laser, cryocoagulation, etc.) can lead to IOP increase [2]. Planned surgery, in the case it is needed, should ideally be effective in not only relieving the symptoms, but also maintaining bleb function.

2. Objective

The objective of this study is to present the characteristics and outcomes of consecutive cases of bleb dysesthesia refractory to medical lubricant treatment that underwent bleblimiting conjunctivoplasty surgery from 2015 to 2019 and, secondarily, to perform an extensive online literature search to identify other studies reporting on the surgical management of bleb dysesthesia.

3. Methods

This case series is a prospective study of consecutive patients that developed refractory bleb dysesthesia after successful filtration surgery in a 4-year time period. This study was approved by the Ethical Committee and was conducted in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained from all the participants.

3.1. Patient Examination. All the participants underwent a thorough ophthalmic evaluation before and 1 day, 1 month, 6 months, and 1 year after conjunctivoplasty: best-corrected visual acuity (BCVA) in Snellen (imperial) scale, standard automated perimetry with Swedish Interactive Threshold Algorithm (SITA) standard strategy, program 24–2 of the Humphrey Field Analyzer (Carl Zeiss Meditec, Germany), Goldman applanation tonometry, slit-lamp biomicroscopy with IBAGS scale [6] for bleb evaluation, gonioscopy, fundoscopy with vertical cup to disc ratio estimation by two glaucoma specialists (MP, AA), and HD-OCT imaging using the standard peripapillary protocol (retinal nerve fiber layer (RNFL) thickness) of Cirrus OCT (Carl Zeiss Meditec, Germany).

3.2. Surgical Technique. The conjunctivoplasty surgery consisted of the following (video attached):

- (i) One radial conjunctival incision through the bleb at 10:30 (left eye) or 1:30 (right eye) position down to bare sclera in the desired limit of bleb (to decrease the size of bleb) (all 4 eyes)
- (ii) Suturing with buried, interrupted sutures, the nearest edge of the filtering bleb (all 4 eyes)
- (iii) Lower limbal peritomy including unwanted area of the extended bleb (all 4 eyes)
- (iv) Dissection of conjunctiva from underlying connective tissue (all 4 eyes), excision of subconjunctival fibrous tissue (in 2 eyes with thick bleb)
- (v) Repositioning of conjunctiva with interrupted resorbable sutures attached to sclera (all 4 eyes)

3.3. Variable Outcomes. Ocular discomfort was expressed freely by patients when dysesthetic bleb was diagnosed and then asked again after conjunctivoplasty at each postoperative visit. Postoperative data including IOP, bleb appearance, VF results, and OCT results was collected at the first 24 hours and then 1, 6, and 12 months after bleb reductive surgery.

3.4. Literature Search. The search for studies to review was performed on the Medline and Embase databases up to March 2020, with no language limits, combining 2 groups of terms: [bleb] AND [dysesthesia]. All terms were used as MeSH and as free terms. All articles were revised by 2

investigators independently (AD, MP). Considering the rarity of this condition, articles were included if they were prospective or retrospective case studies presenting outcomes of surgical treatment of circumferential dysesthetic blebs after filtering procedure. Additionally, data of surgical management and outcomes were extracted from the article body.

4. Results

Four consecutive patients with refractory bleb dysesthesia were included in this study during the 4-year time period. We present their baseline characteristics and postoperative outcomes of a modified bleb-limiting conjunctivoplasty procedure and an overview of previously described cases in the literature.

4.1. Case Series. The study group consisted of 4 eyes of 2 women and 2 men whose ages ranged from 69 to 81 years (mean \pm SD, 72.7 \pm 7.4 years). All patients were from European descent and had primary open-angle glaucoma treated with combined phacoemulsification and trabeculectomy with Mitomycin C (MMC) as primary procedure (see Table 1). During the early postoperative period, additional treatment with 5-fluorouracil (5-FU) and argon laser suturolysis was needed to achieve IOP control in 3 of the 4 eyes. Three months postoperatively, bleb was diffuse and elevated in all cases, with IOP under target.

After a mean of 9.3 ± 8.5 months from primary filtration procedure, the 4 cases developed circumferential, prominent blebs with a mean extension of 168° and nasal (n=3) or temporal (n=1) displacement (Figure 1 (a–d)) associated with ocular discomfort with intense foreign body sensation. Main characteristics of bleb dysesthesia are shown in Table 1. Two patients presented with a corneal Dellen (50%).

Symptomatic relief was not referred by any patient, although intensive lubrication was used, so bleb-limiting conjunctivoplasty was then indicated and performed. No intraoperative complications were noted. In all cases, immediate relief and cosmetic improvement were observed within the first-month follow-up (Figure 1 (e, f)). Although bleb size was reduced intentionally, long-term significant IOP elevation was not observed in any case. Only one eye experimented a self-limited IOP spike (IOP of 26 mmHg) one day after surgery that resolved spontaneously within 24 hours (Case 4). Average IOP was 16.3 ± 7.1 , 10.5 ± 2.5 , 11.5 ± 1.9 , and 11.5 ± 1.9 mmHg for postoperative day 1 and months 1, 6, and 12 after surgery, respectively. None of the cases needed any additional glaucoma medication or surgery after 1 year of follow-up. Visual acuity, visual field, and OCT did not show significant deterioration after 1 year. Surgical outcomes are listed in Table 1.

4.2. Literature Search. The complete flowchart is presented in Figure 2. Our search yielded 34 records and provided 15 additional titles after hand-searching their related references (total of 49 studies). Of these, 17 records were excluded directly after titles and abstracts evaluation. Two reviewers

TABLE 1. Demographic characteristics	dysesthetic bleb characteristics and	surgical outcomes of series of consecutive cases.
INDEL 1. Demographic characteristics	dysestilette bieb endracteristics, and	surgical outcomes of series of consecutive cases.

	Case 1	Case 2	Case 3	Case 4
Demographic characteristics				
Sex/age	M/69	M/69	F/72	F/81
Type of glaucoma	POAG	POAG	POAG	POAG
IOP (mmHg)	21	17	18	16
Topical treatment	$PG + \beta + \alpha$	$PG + \beta + \alpha$	$PG + CAI + \alpha$	$PG + \beta + CAI$
BCVA	20/50	20/32	20/40	20/40
Primary procedure	PT + MMC	PT + MMC	PT + MMC	PT + MMC
Additional treatment	LSL#3 + 5FU#7	LSL#1 + 5FU#2	LSL#1 + 5FU#1	No
BCVA	20/25	20/25	20/40	20/40
IOP (mmHg)	9	10	6	12
VCDR	0.85	0.95	0.9	0.8
OCT	50	47	52	54
VF-MD (dB)	-16.75	-23.3	-30.44	-28.10
Dysesthetic bleb characteristics				
Elapsed time (mo) from primary surgery	13	11	4	9
IBAGS	$2(H) \times 3(E)$	$2(H) \times 3(E)$	$3(H) \times 3(E)$	$3(H) \times 3(E)$
Extension	110°	180°	200°	180°
Signs	Red eye	Red eye	Red eye Dellen	Red eye Dellen
Symptoms	FBS	FBS	FBS	FBS
Lubrication topical treatment	SH 1gtt/h + C 1app/n	SH 1gtt/h + C 1app/n	SH 1gtt/h + C 1app/n	SH 1gtt/h + C 1app/n
Elapsed time (mo) to bleb reduction	2	1	1.5	3
Surgical outcomes				
Type of surgery	CP + E	CP	CP	CP + E
Signs/symptoms	_/_	_/_	_/_	_/_
IOP 24 hrs (mmHg)	12	10	17	26
IOP 1 mo (mmHg)	10	8	10	14
IOP 6 mos (mmHg)	12	10	10	14
IOP 12 mos (mmHg)	12	10	10	14
VCDR	0.85	0.95	0.9	0.8
OCT	50	52	54	56
VF-MD (dB)	-13.25	-23.85	-30.51	-28.97
BCVA	20/25	20/25	20/40	20/40

M: masculine, F: feminine, POAG: primary open-angle glaucoma, IOP (mmHg): intraocular pressure (millimeters of mercury), PG: prostaglandin analogues, β : beta blocker, α : alpha adrenergic agonist, CAI: carbonic anhydrase inhibitor, BCVA: best-corrected visual acuity, PT: phaco + trabeculectomy, MMC: mitomycin C, LSL: laser suturolysis, 5FU: 5 fluorouracil, VCDR: vertical cup to disc ratio, OCT: optical coherence tomography, VF-MD(dB): visual field mean deviation (decibels), mos: months, IBAGS: Indiana Bleb Appearance Grading Scale [6], H: height, E: horizontal extent, FBS: foreign body sensation, SH 1gtt/h: sodium hyaluronate 1drop every hour, C 1app/n: carbomer 1 application every night, CP + E: conjunctivoplasty + excision of subconjunctival connective tissue, and CP: conjunctivoplasty.

(AD, MP) independently evaluated these 32 studies. After this full-text assessment, 17 further records were excluded as they did not meet our study inclusion criteria. Finally, this review of available literature resulted in a total of 15 articles [3–5, 7–18] containing 123 cases of surgical management of circumferential, dysesthetic blebs after penetrating filtering glaucoma surgery (Table 2). We assessed all eligible studies, extracted characteristics, and summarized key findings.

5. Discussion

Bleb dysesthesia is a rare complication of glaucoma surgery in which a well-functioning bleb with well-controlled IOP causes ocular discomfort typically related to an increase in its size [1–4].

Although bleb dysesthesia etiology is still not fully elucidated, two potential productive mechanisms have been described: first, a hypocellular tissue response probably related to the use of antimetabolites creating an avascular bleb that then reaches a larger size [2]; second, a connective tissue hypertrophy caused by an extensive scarring reaction in a susceptible eye [2]. In this direction, histology studies have reported a dense cellular connective tissue even within functioning blebs [2]. It is suggested that such tissue, if presented under the conjunctiva, encourages the formation of dysesthetic blebs physically contributing to the bleb height, and facilitating the formation of a subconjunctival reservoir for aqueous humour beneath its smooth surface [4]. In our study, MMC was used intraoperatively in all 4 cases at the time of the first filtering procedure, and 3 of the 4 eyes received one or more 5-FU postoperative injections to modulate filtration. In fact, two blebs that had undergone application of both antimetabolites showed mostly the hypocellular component. On the other hand, at the moment of the surgical bleb revision, 2 blebs presented a thick connective tissue suggesting a predominance of the fibrous mechanism.

Regarding dysesthetic blebs baseline characteristics, in our study the 4 cases presented blebs that were not so high but very wide, on average 2.5×3 according to IBAGS scale




FIGURE 1: Dysethetic bleb before surgical treatment: nasal (a-c) or temporal (d) extension, hyperemia (a, b) and Dellen (c, d). 1st month (e, f) and 12th month (g, h) after bleb-limiting conjunctivoplasty.




FIGURE 2: Flowchart showing literature search.

[6]; 3 of 4 eyes had a prominent nasal extension and 2 of 4 eyes had corneal Dellen (Figure 1 (a–d)). This is in accordance with some studies that have looked into which bleb features are more likely to cause ocular discomfort and that have found that although dysesthesia is not significantly associated with bleb height [19]; pain does occur more often in larger and circumferential blebs with intrapalpebral exposition and corneal expansion [3], especially if corneal Dellen and a more nasal location are present [3, 19].

Many treatments have been described to manage this condition. Aggressive surface lubrication is an initial, widely accepted, conservative measure that brings only temporary relief to most cases. Other nonsurgical approaches like topical trichloroacetic acid and injection of autologous blood can be used to reduce bleb height by stimulating scarring, but they can also result in filtration failure [2, 5]. Furthermore, laser applications have been suggested but may require multiple sessions with subsequent inflammation and less predictable IOP control [2]. Corneal Dellen is an uncommon complication of extensive blebs [2, 20] and its satisfactory treatment is extremely important to prevent corneal ulceration and subsequent potential perforation [2]. If lubrication is ineffective, a contact lens (conventional or bandage) can be used [21] but its adequate fitting is often challenging in these cases due to bleb-related conjunctival irregularity [22], so definitive reductive surgery should be taken into account.

In cases of highly symptomatic blebs, surgery is the only effective treatment. Globally, in our systematic review we found a complete surgical success rate (without hypotensive medication) between 43% [11] and 100% [10, 14, 16] depending on the technique used (see Table 2). The worse surgical results were observed in partial or entire bleb excision with advancement of conjunctiva as in Canut et al. [11] (43%), Radhakrishnan et al. [12] (57%), and Catoira et al. [17] (67%) studies. Although this more aggressive approach may be adequate for bleb leaks repair (success rate of 83% [11]), our literature evaluation suggests that performing bleb removal may be counterproductive in dysesthetic blebs in which IOP is well controlled, very likely due to the excessive elimination of conjunctival tissue that was actually working properly. This reasoning supports the idea that in bleb dysesthesia the problem is an excessive size rather than a bad function favoring techniques that preserve bleb conjunctiva.

There are several methods for limiting bleb size without removing conjunctival tissue. Bleb compression sutures have been used as an effective alternative [5, 7, 8], but despite having a success rate of 100% in Faingold and Kasner study [8], 3 out of 4 patients experienced complications (2 reoperations and one bleb leak). "Bleb window"-pexy is a different minimally invasive procedure that is able to reduce the bleb with success rates between 89% [9] and even 100% [10] and a low rate of complications. Another widely used surgical approach is bleb-limiting conjunctivoplasty [18] that has shown excellent outcomes with complete success rates of more than 90% possibly being less effective in blebs with thicker walls and denser appearance [3]. With this hypothesis, Lloyd et al. added conjunctival dissection and

F-U	29.4±23.7 m	45 w (8–81)	$40.7\pm17.5~\mathrm{m}$	15.5 m (5–26)	$6.6 \pm 1.7 \text{ m} (3.5 \text{ to } 8.3)$	43.7 ± 29.9 m	2.8 ± 2.7 y	$23 \pm 1.4 \mathrm{m}$	31 m	18.1 ± 11.7 m	52 ± 11.3 m	$17.3 \pm 23.2 \mathrm{m}$	>3 m	>1 y	9.5 ± 3.5 m	ry), preop.: on, 5FU: 5 e choroidal he IOP (no solution of L Complete indication, was defined as defined success was success was and less of and less
Meds	0	0	N/A	1 1	0 6.	4	ŝ	0	0	0	0	1	0	ŝ	N/A	f mercu ulsification on of th ntrol of i uplete re unut et al primary ess rate v ed as the for repe
Success (%)*	N/A	N/A	100%	89%	100%	43% (3/ 7)	57% (16/ 28)	38.3%	100%	N/A	100%	67%	93.3%	100%	N/A	neters of haccoemul quate cor ed as com ation of J lete succe vas defini- tion et al. S y (except
Final IOP	12 ± 4.7	11.3 (5-16)	8.7±3.5	13.4 (10–16)	12.2 ± 2	N/A	13.4 ± 5.9	12 ± 2.8	13	13.2±4.6	11 ± 0	17 ± 3.5	N/A	N/A	14 ± 4.2	irre (millir cin C, P: F ving a tota otoms, ade was define a define b revisior The comp van de Gei min a surgery
IOP 12 m	12 ± 4.7	N/A	N/A	N/A		15.6±6.1	N/A	N/A	N/A	N/A	N/A	N/A	10.2 ± 6.6	12.6 ± 3.1	N/A	lar pressu mitomyc ef of symp success v urgical blo vder et al. uccessful gery. *EJ gery. *EJ
IOP 6 m	N/A	N/A	N/A	N/A	11 ± 6.2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11.5 ± 2.7	N/A	intraocu s, MMC: s, defined cerve reliance cerve reliance complete tions or s introme w or set for repea for repea
IOP 3 m	11.1 ± 2.5	N/A	N/A	N/A	9.5 ± 4.4	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9.2 ± 5.0	11.8 ± 4.8	N/A	mmHg): cuestion with the second secon
IOP 1 m	11±2.5	N/A	N/A	N/A	10.0 ± 4.7	14.9 ± 3	N/A	N/A	N/A	N/A	N/A	N/A	9.2 ± 5.0	12.8 ± 5.3	N/A	y, IOP (1 T: trabec as definete su as definete su as definete as as definete su as definete su baucoma glaucoma de compli dication.
IOP 24 h	N/A	17.3 (9-25)	N/A	N/A	10.33 ± 4.4	14.8±3.5	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	resurger asculine, t al. A co, t al. A co inccess w inccess w inccess w inccess w increase the anti the abser of symptu
Presx IOP	11 ± 2.7	6.7 (0-12)	4.2 ± 0.6	13.9 (8-26)	9.8 ± 4.4	14.0 (8-18)	11.9 ± 4.7	10 ± 4.2	10	11.5 ± 4.3	11 ± 4.2	12.7 ± 1.2	9.4 ± 4.7	10.6 ± 3.4	12 ± 4.4	 press: p ne, M: ma ne, M: ma aingold e azi et al. S azi et al. S rithout fuu rithout fuu rithout fuu s Radhak t any glau t any glau cations in
Comp ReSx	2 needlings	8 autologous blood	2 resx, 1 leak	1 misdirection	No	1 filtering sx	3 filtering sx, 2 resx, 6 still pain, 3 other (blebitis)	1 needling	No	5 resx	No	6.6% ptosis, 13% hypertropia**	 leak resolved spontaneously 	No	1 resx	resx: resurgery ision, F: feminin ta available. *D F drops. *ICl-Har edications or sur and 20 mm Hg w na medications. no development al acuity withoui glaucoma medic glaucoma medic edion, re
Type of Sx	Bleb compression sutures, autologous blood	Bleb compression sutures, autologous blood	Transconj trab flap suturing	Bleb window cryopexy	"Bleb window"-pexy	Partial bleb excision + conj advancement	Excision of the entire bleb (22) or partial (6) with conj advancement	Bleb reduction and free conjunctival	autologous graft Bleb revision with sliding conj flap and fibrin glue Bleb reduction	(excision with conjunctiva advancement in 10 and conjunctival autoorraft in 11)	Bleb excision and conjunctiva and Tenon advancement	Bleb revision by conj advancement	Bleb-limiting conjunctivoplasty	Bleb-limiting conjunctivoplasty with removal of subconj scar	tissue Bleb-limiting conjunctivoplasty	<i>N</i> : number of eyes included, primary procedure, sx: surgery, Comp: complications, resx: resurgery, presx: presurgery, IOP (mmHg): intraocular pressure (millimeters of mercury), preop: preopratively, Meds: antiglaucoma medications, F-U: follow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 5 fullow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 6 fullow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 6 fullow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 6 fullow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 6 fullow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 6 fullow-up, retro: retrospective study, rev-revision, F: family for the study resolution of the loP (no greater than 16 mm Hg), and restoration of filtering bleb function without further antiglaucoma medications or surgical bleb revision. *R Tabet et al. Complete success was defined as complete resolution of symptoms and flattening of the interpalpebral portion of the bleb while maintaining an IOP between 8 and 20 mm Hg without further antiglaucoma medications. *S Radhakrishnan et al. Successful outcome was defined as elimination, no recess mas defined as maintenance of individual target IOP while maintaining an IOP between 8 and 20 mm Hg without further antiglaucoma medications. *S Radhakrishnan et al. Successful outcome was defined as elimination, no recess mas defined as maintenance of not partite success was defined as maintenance of not presenting sucress urgery, no major complication, and no development
Time to Sx	18 m	461 d (41–2023)	3 ± 2 m		$1.6\pm1.8\mathrm{y}$	32 (24-108) m	$3.5 \pm 3.7 y$	31 ± 12.7 m	N/A	2.8±2 <i>y</i>	$14.5 \pm 12 \mathrm{m}$	29.1 m (3-114)	$2.6 \pm 3.0 \text{ y} (3 \text{ m-8.6 y})$	24 w (11 w- 16 m)	$24 \pm 17 \mathrm{m}$: surgery, C etro: retrosp etes, m: mon out the addit without furth le maintainir le maintainir icond revisior cond revisior gery, no majo gery, no majo spectra and out the the same of the the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same of the same
Primary proc	T + MMC	Т	T + MMC/ T + MMC + P	Т	4 T + MMC, 2 T + 5FU	T+MMC, T+MMC+, NPDS+MMC+ SK-gel+P, NPDS+SK- gel	T $(69\%)^{**} + MMC$ (58%) ^{**} +P $(24\%)^{**}$	1 TMMC, 1 T	T + MMC/5FU	8 T/3 TP 5 MMC/2 5FU	T + MMC (75%)**	1 T, 1 T P, 1 T MMC	T + MMC/5FU	T+MMC	2 T	<i>N</i> : number of eyes included, primary procedure, sx: surgery, Comp: complications, resx: resurgery, presx: presurgery, IOP (mmHg): intraocular pressure (millimeters of mercury), preop: preoperatively, Meds: antiglaucoma medications, F-U: follow-up, retro: retrospective study, rev-revision, F: feminine, M: masculine, T: trabeculectomy, MMC: mitomycin C, P: phacoemulsification, 5FU: 5 fluorouracil, NPDS: nonpenetrating deep sclerectomy, d: days, w: weeks, m: months, y: years, N/A: not available. *D Faingold et al. A complete success was defined as achieving a total resolution of the choroidal effusions or a total resolution of symptoms related to dysesthesia without the addition of IOP-lowering drops. *ICI-Harazi et al. Success was defined as subjective relief of symptoms, adequate control of the IOP (no greater than 16 mm Hg), and restoration of filtering bleb function without further antiglaucoma medications or surgical bleb revision. *R Tabet et al. Complete success was defined as complete symptoms and flattening of the interpalpebral portion of the bleb while maintaining an IOP between 8 and 20 mm Hg without further antiglaucoma medications. *S Radhakrishnan et al. Successful outcome was defined as complete resolution symptoms and flattening of the interpalpebral portion of the bleb while maintaining an IOP between 8 and 20 mm Hg without further antiglaucoma medications. *C Schnyder et al. The complete success was defined success defined as maintenance of individual target IOP without a second revision, surgery, or glaucoma medications. *S Radhakrishnan et al. Successful outcome was defined as the resolution or requirement for further intraocular pressure (IOP-) lowering surgery, no major complications. *G Schnyder et al. A morplete success was by an IOP >6 mm Hg and <21 mm Hg, with a visual acuity equal to or better than the preoperative visual acuity without any glaucoma medication. *G Schnyder et al. Successful outcome was defined by an IOP >6 mm Hg and <21 mm Hg, with maintenance of IOP with the same or r
Ν	7	11	4	6	9	ь Г. 8	28	2	-	11	5	3	15	13	4	prim ttions, lerectc elated i f filteri al port ure- (I ure- (I ure- 6 a visua h main
Age	67 (60–77)	68 (47–78)	N/A	71 (56-81)	57.1 ± 12.4	63 (44-78)	67±14**	$62 \pm 15.4^{**}$	69	57 (14-82)**	59.6 (21-79)**	45.3 ± 21	67.6 (51-81)	60 ± 11.0	67 ± 5.7	mary pro- ma medic mg deep sc mptoms r toration o terpalpebr individua ular press (Hg, with vision, with vision, with vision, with
Sex	6F 1M	5F 6M	N/A	4F 5M	5F 1M	3F 4M	90F (54%)**	12F 4M**	MI	18F 13M**	17F 1M**	12F 18M**	7F 8M	3F 8M	2F	uded, pri itiglaucor penetratiu tion of sy , and rest of the int =nance of er intraoc er intraoc 1 < 21 mm on for rev ular press
Type	Retro case series	Retro case series	Retro rev	Retro rev	Retro rev	Retro case series	Retro case series	Retro rev	Retro case series	Retro case series	Retro rev	Retro rev	Retro rev	Retro rev	Case series	eyes incl- eyes incl- Meds: an DDS: non tal resolu mm Hg for furth- for furth- m Hg anc g indicati al intrao.
Study	S Begum et al. [5]	JE Morgan et al. [7]	D Faingold et al. [8]	IC l-Harazi et al. [9]	R Tabet et al. [10]	MI Canut et al. [11]	S Radhakrishnan et al. [12]	CC Schnyder et al. [13]	GA Lee et al. [14]	SE LaBorwit et al. [15]	EJ van de Geijn et al. [16]	Y Catoira et al. [17]	S Anis et al. [3]	M Lloyd et al. [4]	R Rahman et al. [18]	<i>N</i> : number of a preoperatively, fluorouracil, NF effusions or a to greater than 16 symptoms and f success defined no requirement by an IOP > 6 mi of the presenting defined as a fina euroery ¹ *V of al

Journal of Ophthalmology

further excision of any subjacent subconjunctival tissue to all their procedures (n = 13) obtaining very good results (100% success) but still with 3 cases needing additional hypotensive topical treatment [4]. Encouraged by these outcomes, we decided to perform a bleb-limiting conjunctivoplasty as elective surgical treatment for our patients, but deciding intraoperatively to add removal of subconjunctival fibrous tissue only in the cases in which it was clearly identifiable at the time of the procedure (n = 2/4, 50%) with the idea to individualize treatment depending on the most predominant causing mechanism. In all of our four cases, discomfort relief and good IOP control were achieved and maintained after one year of follow-up without any additional glaucoma treatment or significant glaucomatous deterioration.

Our study has several limitations. First, due to the rarity of the condition, a small number of cases were included in the study, and this needs to be considered when interpreting the results. And second, our systematic review could not find enough reliable and prospective information to provide more robust data. To partly address these limitations, a thorough and comprehensive evaluation and summary of the available data in the literature was provided.

In conclusion, bleb dysesthesia is an uncommon complication that very likely needs surgery due to failure of medical treatment. Aggressive surgical techniques removing bleb tissue may be less effective in terms of subsequent IOP control. A modified bleb-limiting conjunctivoplasty technique may be a treatment for bleb dysesthesia and allows deciding intraoperatively which mechanisms, avascular or fibrous, predominate, choosing then the most appropriate procedure of bleb reduction, with or without excision of subconjunctival fibrous tissue in each case. After 12-month follow-up, this technique provided dysesthesia relief with good IOP control in the four studied cases.

Data Availability

All data relevant to this study are included within the article or uploaded as online supplementary information. The data are also available from the corresponding author upon reasonable request (agnieszkaannadyrda@wp.pl).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary Materials

The supplementary file is the video explaining the surgical method discussed in the article. (Supplementary Materials)

References

- J. S. Cohen, R. N. Shaffer, J. Hetherington Jr., and D. Hoskins, "Revision of filtration surgery," *Archives of Ophthalmology*, vol. 95, no. 9, pp. 1612–1615, 1977.
- [2] A. Azuara-Blanco and L. J. Katz, "Dysfunctional filtering blebs," *Survey of Ophthalmology*, vol. 43, no. 2, pp. 93–126, 1998.

- [3] S. Anis, R. Ritch, W. Shihadeh, and R. J. Liebmann, "Surgical reduction of symptomatic, circumferential, filtering blebs," *Archives of Ophthalmology*, vol. 124, no. 6, pp. 890–894, 2006.
- [4] M. Lloyd, M. Giegengack, and J. C. Morrison, "Surgical reduction of dysesthetic blebs," *Archives of Ophthalmology* (*Chicago, Ill.: 1960*), vol. 126, no. 12, pp. 1759–1764, 2008.
- [5] S. Begum, H. Bobat, and J. F. Kirwan, "Bleb compression and autologous blood for relief of bleb dysaesthesia. Does it work?" *Clinical & Experimental Ophthalmology*, vol. 44, no. 6, pp. 528-529, 2016.
- [6] L. B. Cantor, A. Mantravadi, D. WuDunn, K. Swamynathan, and A. Cortes, "Morphologic classification of filtering blebs after glaucoma filtration surgery: the Indiana bleb appearance grading scale," *Journal of Glaucoma*, vol. 12, no. 3, pp. 266– 271, 2003.
- [7] J. E. Morgan, J. P. Diamond, and S. D. Cook, "Remodelling the filtration bleb," *British Journal of Ophthalmology*, vol. 86, no. 8, pp. 872–875, 2002.
- [8] D. Faingold and O. P. Kasner, "Expanded indications for transconjunctival trabeculectomy flap suturing: postoperative choroidal effusion and dysesthesia," *Canadian Journal of Ophthalmology*, vol. 47, no. 3, pp. 291–295, 2012.
- [9] S. M. El-Harazi, R. L. Fellman, R. M. Feldman, Y. N. T. Dang, and A. Z. Chuang, "Bleb window cryopexy for the management of oversized, misplaced blebs," *Journal of Glaucoma*, vol. 10, no. 1, pp. 47–50, 2001.
- [10] R. Tabet, R. M. Feldman, N. P. Bell, and D. A. Lee, ""Bleb window"-pexy for the management of symptomatic, oversized blebs," *Journal of Glaucoma*, vol. 18, no. 7, pp. 546–551, 2009.
- [11] M. I. Canut, R. Cobián, A. Fernández-Vega, G. Julio, and R. I. Barraquer, "Long-term follow-up of partial bleb excision in late-onset bleb-related complications by a single surgeon using conjunctival advancement," *Journal of Glaucoma*, vol. 28, no. 6, pp. 546–549, 2019.
- [12] S. Radhakrishnan, H. A. Quigley, H. D. Jampel et al., "Outcomes of surgical bleb revision for complications of trabeculectomy," *Ophthalmology*, vol. 116, no. 9, pp. 1713–1718, 2009.
- [13] C. C. Schnyder, T. Shaarawy, E. Ravinet, F. Achache, S. Uffer, and A. Mermoud, "Free conjunctival autologous graft for bleb repair and bleb reduction after trabeculectomy and nonpenetrating filtering surgery," *Journal of Glaucoma*, vol. 11, no. 1, pp. 10–16, 2002.
- [14] G. A. Lee and D. J. Holcombe, "Surgical revision of dysfunctional filtration blebs with bleb preservation, sliding conjunctival flap and fibrin glue," *Eye*, vol. 24, no. 6, pp. 947–953, 2010.
- [15] S. E. La Borwit, H. A. Quigley, and H. D. Jampel, "Bleb reduction and bleb repair after trabeculectomy," *Ophthalmol*ogy, vol. 107, no. 4, pp. 712–718, 2000.
- [16] E. J. van de Geijn, H. G. Lemij, J. de Vries, and P. W. T. de Waard, "Surgical revision of filtration blebs: a follow-up study," *Journal of Glaucoma*, vol. 11, no. 4, pp. 300–305, 2002.
- [17] Y. Catoira, D. Wudunn, and L. B. Cantor, "Revision of dysfunctional filtering blebs by conjunctival advancement with bleb preservation," *American Journal of Ophthalmology*, vol. 130, no. 5, pp. 574–579, 2000.
- [18] R. Rahman and V. T. Thaller, "Bleb-limiting conjunctivoplasty for symptomatic circumferential trabeculectomy blebs," *Journal of Glaucoma*, vol. 12, no. 3, pp. 272–274, 2003.

- [19] D. L. Budenz, K. Hoffman, and A. Zacchei, "Glaucoma filtering bleb dysesthesia," *American Journal of Ophthalmology*, vol. 131, no. 5, pp. 626–630, 2001.
- [20] H. K. Soong and H. A. Quigley, "Dellen associated with filtering blebs," *Archives of Ophthalmology*, vol. 101, no. 3, pp. 385–387, 1983.
- [21] C. R. Fenzl, M. Moshirfar, A. J. Gess, V. Muthappan, and J. Goldsmith, "Dellen-like keratopathy associated with glaucoma drainage devices," *World Journal of Clinical Cases*, vol. 2, no. 1, pp. 1–4, 2014.
- [22] G. D. Kymionis, A. Plaka, G. A. Kontadakis, and N. Astyrakakis, "Treatment of corneal dellen with a large diameter soft contact lens," *Contact Lens and Anterior Eye*, vol. 34, no. 6, pp. 290–292, 2011.